. "case report; metastatic gastric cancer; chemotherapy; S-1-cisplatin"@en . "Case Report of a Patient with Advanced and Disseminated Gastric Carcinoma Treated by S-1"@en . "RIV/00216224:14110/14:00077148" . "RIV/00216224:14110/14:00077148!RIV15-MSM-14110___" . "14110" . . "3"^^ . "Rotn\u00E1glov\u00E1, Simona" . "1"^^ . "Case Report of a Patient with Advanced and Disseminated Gastric Carcinoma Treated by S-1"@en . . . . "Kazuistika pacienta se zna\u010Dn\u011B pokro\u010Dil\u00FDm a diseminovan\u00FDm karcinomem \u017Ealudku l\u00E9\u010Den\u00FDm prepar\u00E1tem S-1"@cs . . "Katolick\u00E1, Jana" . "V\u00FDchodiska: Progn\u00F3za pacient\u016F s metastatick\u00FDm karcinomem \u017Ealudku je velmi nep\u0159\u00EDzniv\u00E1 a \u0159\u00E1dov\u011B se pohybuje v m\u011Bs\u00EDc\u00EDch \u017Eivota. S-1 je peror\u00E1ln\u00ED fl uoropyrimidinov\u00FD protin\u00E1dorov\u00FD p\u0159\u00EDpravek. Jde o fixn\u00ED kombinaci t\u0159\u00ED \u00FA\u010Dinn\u00FDch l\u00E1tek \u2013 tegafuru, gimeracilu a oteracilu draseln\u00E9ho. Popis p\u0159\u00EDpadu: Prezentujeme p\u0159\u00EDpad 71let\u00E9ho mu\u017Ee l\u00E9\u010Den\u00E9ho pro lok\u00E1ln\u011B zna\u010Dn\u011B pokro\u010Dil\u00FD a sou\u010Dasn\u011B metastatick\u00FD karcinom \u017Ealudku v prvn\u00ED linii pomoc\u00ED kombinovan\u00E9ho re\u017Eimu S-1 a cisplatiny. L\u00E9\u010Debn\u00E1 odpov\u011B\u010F dos\u00E1hla parci\u00E1ln\u00ED remise a trvala \u0161est m\u011Bs\u00EDc\u016F. Vlastn\u00ED l\u00E9\u010Dba byla velmi dob\u0159e tolerov\u00E1na, bez toxicity stupn\u011B 3 a 4 (grade 3 a 4). Po progresi tak pacient mohl podstoupit dal\u0161\u00ED linii protin\u00E1dorov\u00E9 l\u00E9\u010Dby. Z\u00E1v\u011Br: Zku\u0161enosti s p\u0159\u00EDpravkem S-1 jsou v populaci \u010Desk\u00FDch pacient\u016F dosud velmi limitovan\u00E9. Na\u0161e kazuistika poukazuje na dobrou l\u00E9\u010Debnou odpov\u011B\u010F a minim\u00E1ln\u00ED toxicitu zvolen\u00E9 l\u00E9\u010Dby a je tak v souladu s v\u00FDsledky studie FLAGS."@cs . "Kazuistika pacienta se zna\u010Dn\u011B pokro\u010Dil\u00FDm a diseminovan\u00FDm karcinomem \u017Ealudku l\u00E9\u010Den\u00FDm prepar\u00E1tem S-1"@cs . "Kazuistika pacienta se zna\u010Dn\u011B pokro\u010Dil\u00FDm a diseminovan\u00FDm karcinomem \u017Ealudku l\u00E9\u010Den\u00FDm prepar\u00E1tem S-1" . "3"^^ . "3" . "V\u00FDchodiska: Progn\u00F3za pacient\u016F s metastatick\u00FDm karcinomem \u017Ealudku je velmi nep\u0159\u00EDzniv\u00E1 a \u0159\u00E1dov\u011B se pohybuje v m\u011Bs\u00EDc\u00EDch \u017Eivota. S-1 je peror\u00E1ln\u00ED fl uoropyrimidinov\u00FD protin\u00E1dorov\u00FD p\u0159\u00EDpravek. Jde o fixn\u00ED kombinaci t\u0159\u00ED \u00FA\u010Dinn\u00FDch l\u00E1tek \u2013 tegafuru, gimeracilu a oteracilu draseln\u00E9ho. Popis p\u0159\u00EDpadu: Prezentujeme p\u0159\u00EDpad 71let\u00E9ho mu\u017Ee l\u00E9\u010Den\u00E9ho pro lok\u00E1ln\u011B zna\u010Dn\u011B pokro\u010Dil\u00FD a sou\u010Dasn\u011B metastatick\u00FD karcinom \u017Ealudku v prvn\u00ED linii pomoc\u00ED kombinovan\u00E9ho re\u017Eimu S-1 a cisplatiny. L\u00E9\u010Debn\u00E1 odpov\u011B\u010F dos\u00E1hla parci\u00E1ln\u00ED remise a trvala \u0161est m\u011Bs\u00EDc\u016F. Vlastn\u00ED l\u00E9\u010Dba byla velmi dob\u0159e tolerov\u00E1na, bez toxicity stupn\u011B 3 a 4 (grade 3 a 4). Po progresi tak pacient mohl podstoupit dal\u0161\u00ED linii protin\u00E1dorov\u00E9 l\u00E9\u010Dby. Z\u00E1v\u011Br: Zku\u0161enosti s p\u0159\u00EDpravkem S-1 jsou v populaci \u010Desk\u00FDch pacient\u016F dosud velmi limitovan\u00E9. Na\u0161e kazuistika poukazuje na dobrou l\u00E9\u010Debnou odpov\u011B\u010F a minim\u00E1ln\u00ED toxicitu zvolen\u00E9 l\u00E9\u010Dby a je tak v souladu s v\u00FDsledky studie FLAGS." . "Kazuistika pacienta se zna\u010Dn\u011B pokro\u010Dil\u00FDm a diseminovan\u00FDm karcinomem \u017Ealudku l\u00E9\u010Den\u00FDm prepar\u00E1tem S-1" . "27" . . "Background: Prognosis of patients with metastatic gastric cancer is abysmal, usually just a few months. S-1 is a peroral fl uoropyrimidine antitumor drug. It is a fi xed combination of three eff ective drugs \u2013 tegafur, gimeracil and oteracil potassium. Case: This is a case report of a 71-year-old man treated for local advanced and metastatic gastric carcinoma treated with combination of S-1 and cisplatin as a fi rst line of therapy. Treatment response reached partial remission and lasted for six months. Treatment was very well tolerated, with no grade 3 and 4 toxicity. After progression, the patient was treated with further lines of therapy. Conclusion: In the Czech Republic, experience with S-1 drug is very limited. Our case report showed a good treatment response and minimal toxicity of this treatment, in concordance with results of the study FLAGS."@en . "Van\u00ED\u010Dek, Ji\u0159\u00ED" . . . "CZ - \u010Cesk\u00E1 republika" . . "[186E4C14D7E1]" . "24121" . "Klinick\u00E1 onkologie" . . "0862-495X" . . . . . "I" .